INT49238

Context Info Confidence 0.97 First Reported 1993 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 30 Total Number 30 Disease Relevance 15.64 Pain Relevance 3.45

extracellular space (COL1A2) extracellular region (COL1A2) protein binding, bridging (COL1A2)

Anatomy Link Frequency cartilage 2 joint 1 Cleavage 1 skeleton 1 fibroblasts 1 COL1A2 (Homo sapiens)

Pain Link Frequency Relevance Heat metalloproteinase 392 99.80 Pain 58 94.40 rheumatoid arthritis 142 93.68 cytokine 50 92.72 Arthritis 85 89.76 backache 2 89.52 Inflammation 207 89.44 Osteoarthritis 158 85.28 Snapping jaw 5 68.04 fibrosis 1 33.24

Disease Link Frequency Relevance Heat Alpha-1-antitrypsin Deficiency 10 100.00 Acne 24 99.84 Cancer 159 99.80 Hypercalcemia 155 99.72 Breast Cancer 476 99.70 Osteomyelitis 2 96.48 Fever 25 95.44 Osteolysis 19 94.48 Pain 48 94.40 Disease 241 94.16

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

New methods for the measurement of bone resorption, such as the degradation product of type I collagen (ICTP), may improve the possibility of monitoring the effect of clodronate.

Protein_catabolism (degradation) of type I collagen associated with hypercalcemia

1) Confidence 0.97 Published 1995 Journal Acta Oncol Section Abstract Doc Link 7546830 Disease Relevance 0.88 Pain Relevance 0.09

As shown in Tables 6 and 7, the 17-peptide biomarkers were found to be degradation products of eight different proteins: alpha1 antitrypsin (A1AT, two peptides having overlapping sequences), collagen type I alpha 1 (COL1A1; five peptides and three of them having overlapping sequences), collagen type I alpha 2 (COL1A2; one peptide), collagen type III alpha 1 (COL3A1; one peptide), collagen type IX alpha 2 (COL9A2; one peptide), fibrinogen alpha (FGA; two peptides having overlapping sequences), fibrinogen beta (FGB; two peptides having overlapping sequences), and uromodulin (UMOD; three peptides having overlapping sequences).

Protein_catabolism (degradation) of COL1A2 associated with alpha-1-antitrypsin deficiency

2) Confidence 0.64 Published 2010 Journal Clin Proteomics Section Body Doc Link PMC2970804 Disease Relevance 0.89 Pain Relevance 0.12

As shown in Tables 6 and 7, the 17-peptide biomarkers were found to be degradation products of eight different proteins: alpha1 antitrypsin (A1AT, two peptides having overlapping sequences), collagen type I alpha 1 (COL1A1; five peptides and three of them having overlapping sequences), collagen type I alpha 2 (COL1A2; one peptide), collagen type III alpha 1 (COL3A1; one peptide), collagen type IX alpha 2 (COL9A2; one peptide), fibrinogen alpha (FGA; two peptides having overlapping sequences), fibrinogen beta (FGB; two peptides having overlapping sequences), and uromodulin (UMOD; three peptides having overlapping sequences).

Protein_catabolism (degradation) of collagen type I alpha 2 associated with alpha-1-antitrypsin deficiency

3) Confidence 0.64 Published 2010 Journal Clin Proteomics Section Body Doc Link PMC2970804 Disease Relevance 0.84 Pain Relevance 0.12

Dental amalgam conditioned buffer also inhibited the degradation of denatured type I collagen by purified MMP-2 on liquid phase assays.

Protein_catabolism (degradation) of type I collagen

4) Confidence 0.62 Published 2001 Journal Biomaterials Section Abstract Doc Link 11426881 Disease Relevance 0.20 Pain Relevance 0.21

Another assay specific for fragments of the collagen type I C-telopeptide, ICTP, results primary from nonosteoclastic matrix-metalloproteinase-mediated degradation of type I collagen [34].

Protein_catabolism (degradation) of type I collagen associated with metalloproteinase

5) Confidence 0.37 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC546286 Disease Relevance 0.37 Pain Relevance 0.11

The ability of the cancer cells to degrade the type I collagen is consistent with the expression of proteolytic activity.

Protein_catabolism (degrade) of type I collagen associated with cancer

6) Confidence 0.35 Published 2005 Journal Cancer Cell Int Section Body Doc Link PMC548674 Disease Relevance 0.67 Pain Relevance 0

Collagenase activity was measured by the degradation of fluorescein isothiocyanate (FITC)-labelled type I collagen using type I activity assay kits.

Protein_catabolism (degradation) of type I collagen

7) Confidence 0.35 Published 2005 Journal Cancer Cell Int Section Body Doc Link PMC548674 Disease Relevance 0 Pain Relevance 0.04

(10-10M) and cultured in the presence of 10% FCS the cancer cells induced significant degradation of type I collagen (range 70–80%), whereas minimal degradation was observed in the absence of serum (Fig. 1).

Protein_catabolism (degradation) of type I collagen associated with cancer

8) Confidence 0.35 Published 2005 Journal Cancer Cell Int Section Body Doc Link PMC548674 Disease Relevance 0.73 Pain Relevance 0.06

Type I collagen degradation

Protein_catabolism (degradation) of Type I collagen

9) Confidence 0.35 Published 2005 Journal Cancer Cell Int Section Body Doc Link PMC548674 Disease Relevance 0.85 Pain Relevance 0.15

The remaining matrix was degraded as for the type I collagen assay and matrix degradation expressed as above.

Protein_catabolism (degradation) of type I collagen

10) Confidence 0.35 Published 2005 Journal Cancer Cell Int Section Body Doc Link PMC548674 Disease Relevance 0.17 Pain Relevance 0.04

Hence to determine whether breast cancer cell mediated degradation of type I collagen could be extended to a more physiological system, cancer cells were cultured on bone matrix as described below.

Protein_catabolism (degradation) of type I collagen associated with cancer and breast cancer

11) Confidence 0.35 Published 2005 Journal Cancer Cell Int Section Body Doc Link PMC548674 Disease Relevance 0.66 Pain Relevance 0

Breast cancer cells (105 /16 mm culture well) were seeded onto the bone matrix as for the type I collagen degradation assay.

Protein_catabolism (degradation) of type I collagen associated with breast cancer

12) Confidence 0.35 Published 2005 Journal Cancer Cell Int Section Body Doc Link PMC548674 Disease Relevance 0.10 Pain Relevance 0

The type I collagen degradation marker ICTP (C-terminal telopeptide of type I collagen) and the cartilage markers CTX-II (C-terminal telopeptide fragments of type II collagen) and cartilage oligomeric matrix protein (COMP) were associated with the Larsen score at baseline.

Protein_catabolism (degradation) of type I collagen in cartilage

13) Confidence 0.32 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC546286 Disease Relevance 0.59 Pain Relevance 0.18

Type I collagen degradation assay

Protein_catabolism (degradation) of Type I collagen

14) Confidence 0.31 Published 2005 Journal Cancer Cell Int Section Body Doc Link PMC548674 Disease Relevance 0.06 Pain Relevance 0

Increased degradation of type I collagen in acne fulminans.

Protein_catabolism (degradation) of type I collagen associated with acne

15) Confidence 0.30 Published 1996 Journal Acta Derm. Venereol. Section Title Doc Link 8740265 Disease Relevance 1.27 Pain Relevance 0.09

In the present study the degradation product (ICTP) of type I collagen, the most abundant collagen of the skeleton, was measured from the sera of patients suffering from acne fulminans.

Protein_catabolism (degradation) of type I collagen in skeleton associated with acne

16) Confidence 0.30 Published 1996 Journal Acta Derm. Venereol. Section Abstract Doc Link 8740265 Disease Relevance 1.19 Pain Relevance 0.09

The resorbing process can be investigated using a specific immunoassay for ICTP (cross-linked carboxyterminal telopeptide region of type I collagen) which allows the measurement of the degradation of type I collagen in serum samples.

Protein_catabolism (degradation) of type I collagen

17) Confidence 0.20 Published 1993 Journal Eur. J. Cancer Section Abstract Doc Link 7683480 Disease Relevance 0.89 Pain Relevance 0.30

The resorbing process can be investigated using a specific immunoassay for ICTP (cross-linked carboxyterminal telopeptide region of type I collagen) which allows the measurement of the degradation of type I collagen in serum samples.

Protein_catabolism (degradation) of type I collagen

18) Confidence 0.18 Published 1993 Journal Eur. J. Cancer Section Abstract Doc Link 7683480 Disease Relevance 0.91 Pain Relevance 0.31

Serum samples were analysed at baseline, 3 and 12 months for procollagen type I N-terminal propeptide (P1NP), a marker of bone formation, and the C-telopeptide crosslaps of type I collagen (CTX-1) and C-terminal telopeptide of type I collagen (1CTP), markers of bone degradation.

Protein_catabolism (degradation) of type I collagen

19) Confidence 0.18 Published 2008 Journal Arthritis Res Ther Section Abstract Doc Link PMC2656227 Disease Relevance 0.43 Pain Relevance 0.13

Serum samples were analysed at baseline, 3 and 12 months for procollagen type I N-terminal propeptide (P1NP), a marker of bone formation, and the C-telopeptide crosslaps of type I collagen (CTX-1) and C-terminal telopeptide of type I collagen (1CTP), markers of bone degradation.

Protein_catabolism (degradation) of type I collagen

20) Confidence 0.18 Published 2008 Journal Arthritis Res Ther Section Abstract Doc Link PMC2656227 Disease Relevance 0.54 Pain Relevance 0.14

General Comments

This test has worked.